It's just like what people like Dr T have said in the past. For those that have done their research and understand the full context and the end goal, the announcement was significant, as it provided yet another link between FTO inhibition and the killing of cancer and a further derisking of Zantrene, but for the market who might not have this context their reaction is probably "oh preclinical big deal". I think that is the point Eric is trying to make.
RAC - Charts & Price Action, page-8871
-
- There are more pages in this discussion • 13,583 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
